CancerCompass message board discussion started by 60year on 2/23/2008 http://www.cancercompass.com/message-board/message/all,21252,0.htm Wed, 08 Oct 2008 00:00:00 GMT Wed, 08 Oct 2008 00:00:00 GMT http://backend.userland.com/rss RSS.NET: http://www.rssdotnet.com/ I put this site up yesterday and it was removed.  I wounder why?What do you think of this site? http://www.pcaresearch.com/   60year Sat, 23 Feb 2008 00:00:00 GMT  Firstly the administrator of this site, has the right to remove things, they do not agree with.  That is controversial treatment and has not been approved here yet.(USA)  Having said that I looked into it and it is not as good as regular radiation therapy for prostate cancer and it has more side effects.  The proton Beam is waaay more effective.  That is found at MD Anderson and Loma Linda Medical center, One in Boston and one in Indiana.  Of course the cost is high but Medicare covers it.As my husband will be treated soon we have looked at everything, he along with me, agrees surgery should be the last result and only specific patients benefit from it. There is also Hormone therapy.  So do not be surprised if the link is removed again. Those looking for alternative and regular therapy might want to  contact the Cancer Treatment Centers of America.  The do an awesome Job.  No I did no us them but know several patients who have.  .MMS On 2/23/2008 60year wrote:I put this site up yesterday and it was removed.  I wounder why?What do you think of this site? http://www.pcaresearch.com/    mmsurvivor Sat, 23 Feb 2008 00:00:00 GMT  Only facts..........EDAP Announces First Published Long-Term Study of HIFU for Localized Prostate CancerThursday December 13, 3:15 pm ET  LYON, France, Dec. 13, 2007 (PRIME NEWSWIRE) -- EDAP TMS S.A. (NasdaqGM:EDAP - News) the global leader in High Intensity Focused Ultrasound treatment of prostate cancer announces the release of the first multi-center long-term study of HIFU uses for the treatment of localized prostate cancer. The study's lead author, Dr. Andreas Blana, concludes that Ablatherm-HIFU efficacy is competitive to currently accepted nonsurgical standards of care, such as radiotherapy, but offers patients milder side effects. Dr. Blana stated, ``This study is the first of its kind in examining the long-term results of HIFU treatment. This innovative and revolutionary treatment clearly has the capacity to help men with prostate cancer. Indeed, I would say it is an excellent treatment option for men with localized prostate cancer, and it should be part of a doctor's armory when treating the disease.''The study tracks 140 patients treated at multiple sites in Europe between 1997 and 2001. The study notes that nearly 9 of 10 participants (86%) achieved negative biopsies following Ablatherm treatment, and PSA after 5 years was low or stable in nearly 8 of 10 participants (77%). Follow-up ranged up to 9 years with a mean of 6.4 years and all patients tracked at least 5 years. Median nadir PSA achieved was 0.16 ng/ml with a number of patients achieving 0.0 ng/ml, and 68.4% of patients achieved nadir PSA of below 0.5 ng/ml. The study concludes Ablatherm-HIFU is effective in treating organ confined prostate cancer and is a valid alternative to current treatments such as radiotherapy.In an editorial accompanying the published article, Dr. Vincenzo Ficarra from the University of Padua, Italy said, ``These data confirm the efficacy of HIFU in patients with localized prostate cancer also at long-term follow-up. These oncologic results can be considered competitive with those reported after radical prostatectomy or external-beam radiation therapy.''Dr. Ficarra continued, ``Beyond the oncologic outcomes, the article by Blana et al confirmed the very promising functional data of HIFU treatments in terms of urinary continence and recovery of erectile function.''Dr. John Rewcastle, Medical Director of EDAP, said, ``This is a very significant publication. Not only is it yet another positive report of the efficacy and mild morbidity profile of HIFU, it demonstrates the durability of the procedure in terms of cancer control over a period of many years. This further solidifies the role of HIFU as a primary prostate cancer therapy in countries where it is already approved for routine clinical use. In the United States, HIFU is an investigational device and is being studied under an FDA approved IDE investigation. The data from this study is relevant to the U.S. study as it demonstrated that short-term results are indicative of longer term cancer control.''A summary of the study can be obtained online at European Urology at: http://www.europeanurology.com/article/PIIS0302283807013814/ Company Background:EDAP TMS S.A. develops and markets Ablatherm, the most advanced and clinically proven choice for High Intensity Focused Ultrasound (HIFU) treatment of localized prostate cancer. The company is currently in U.S. FDA Phase II/III Clinical Trials at major U.S. centers including Duke University, Vanderbilt University, Florida Foundation of Healthcare, and others. Participating sites can be viewed online at http://www.clinicaltrials.gov by searching for ``Ablatherm.''Ablatherm-HIFU is fully approved in the EU and other countries worldwide. More than 14,500 treatments have been completed at more than 165 centers globally. Clinical documentation compiled over more than 10 years provides peer reviewed data attesting to efficacy, safety and repeatability of the treatment outcomes among centers.Ablatherm-HIFU is a treatment for patients with newly diagnosed localized prostate cancer or who have failed radiotherapy treatment. The company is also developing this technology for the potential treatment of certain other types of tumors. EDAP TMS S.A. also produces and commercializes medical equipment for treatment of urinary tract stones using Extra-corporeal Shockwave Lithotripsy (ESWL).EDAP TMS S.A. also produces and commercializes medical equipment for treatment of urinary tract stones using Extra-corporeal Shockwave Lithotripsy (ESWL).To sign up for alerts please visit: http://www.b2i.us/irpass.asp?BzID=1053&to=ea&s=0 In addition to historical information, this press release contains forward-looking statements that involve risks and uncertainties. These include statements regarding the Company's growth and expansion plans. Such statements are based on management's current expectations and are subject to a number of uncertainties and risks that could cause actual results to differ materially from those described in these forward-looking statements. Factors that may cause such a difference include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission. Ablatherm-HIFU treatment is in clinical trials but not yet FDA approved or marketed in the United States. Contact: EDAP TMS S.A. Blandine Confort +33 4 78 26 40 46 Magnolia Investor Relations Matt Kreps 469 362 5960Source: EDAP TMS S.A. 60year Sat, 23 Feb 2008 00:00:00 GMT 60 year, do you have any financial or other interest in EDAP or the EDAP HIFU machine? EDAP has been agressively launching their new machine in the US, while the competing Sonablate has been around and has been widely used by american HIFU physicians for years now.As far as proton beam is concerned, it is still highly controversial, even amongst the radiation therapists. It is also very expensive (at leat 3 times more expensive than HIFU), adding to the cost of healthcare. Looking at the websites promoting proton beam I keep seeing how fantastic this is, but at the same time have a very hard time finding data: cancer control numbers, types and frequencies of side effects, etc. hifudoc Sun, 24 Feb 2008 00:00:00 GMT HIFU might not be approved in US however it has been used in Europe and Japan for considerable time and is not regarded as controversial there or in many other places. Johnw100 Sun, 24 Feb 2008 00:00:00 GMT I had Hifu done in Germany last March. My PSA has remained at 0.05 or undetecatble and have not had any side effects, Ciscox Sun, 02 Mar 2008 00:00:00 GMT